COVAXIN successfully completes phase 2/3 trials in U.S.
The results show no adverse effects were seen in clinical trials; the company says the vaccine is an alternative for those hesitant to receive mRNA jabs in the U.S.
covaxin
January 2023
June 2022
April 2022
December 2021
November 2021
October 2021
India’s first mRNA vaccine against Covid-19 from Gennova gets DCGI approval
Gennova's vaccine will be available for adults above 18 years of age. It will be a two-dose vaccine that will be administered intramuscularly at 28 days apart
COVAXIN shows safety, immunogenicity in children aged 2-18 years: Lancet
Peer-reviewed data has been published in Lancet Infectious Diseases; phase II-III study was held to evaluate safety, and immunogenicity of COVAXIN among healthy children and adolescents.
Covaxin, Corbevax get 'emergency use' nod for kids aged 5-12
The CDSCO approval has also been granted for two doses of ZyCov-D for those aged over 12. The decision comes amid a rise in Covid cases in cities like Delhi.
Bharat Biotech's US partner to commercialise Covaxin in Mexico
In addition to the US and Canada, Ocugen will also have the exclusive rights for supply and commercialisation of Covaxin in Mexico.
Children to get Covaxin Covid-19 jabs from Jan 3
Booster shots for healthcare and frontline workers to start from Jan 10; those above 60, with comorbities, eligible too.
Be tough on people not disciplined: Bharat Biotech's Suchitra Ella
Ella was the company’s go-to person during the production of its indigenously developed Covid-19 vaccine, Covaxin—engaging with multiple ministries almost on a daily basis.
Next target for Covid vaccine: 200 crore; How soon?
100 crore shots and rising.
Eager for WHO approval for Covaxin: Suchitra Ella
As countries open their borders to travel, tourism and education, Bharat Biotech’s Covaxin awaits WHO’s nod on October 26. Co-founder, Suchitra Ella, is hopeful of a positive answer.
Rare clots and heart issues by Covid vaccines call for larger trials in kids
Covaxin gets approval for 2-18 year olds; limited clinical trials may be inadequate to detect issues, say experts.
